The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Dose and duration of aspirin use to reduce incidental hepatocellular carcinoma
Fujiwara N1,2, Singal AG1, Hoshida Y1. Hepatology. 2019 Jun 17. doi: 10.1002/hep.30813. [Epub ahead of print]
Author information
1 Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, USA.
2 Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Abstract
Hepatocellular carcinoma (HCC) incidence in the U.S. is increasing in specific subgroups of patients such as white men with hepatitis C and Hispanics with non-alcoholic fatty liver disease.(1) HCC is the only cancer type with increased mortality over the past three decades throughout the nation, and with still dismal 5-year survival less than 18%.(2) HCC chemoprevention in individuals at high risk is likely the most impactful strategy to improve patient prognosis, although no such therapy has been established to date after a series of failed clinical trials of agents such as low-dose interferon.